One World Products Issues Shareholder Update Letter Providing Review of 2022 and Business Outlook for 2023

Expects Extraction and Production Facility to be Operational Before the End of the Third Quarter of 2023

LAS VEGAS, NV , June 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- One World Products, Inc. (the “Company,”) (OTCQB: OWPC), the largest Black-controlled, fully-licensed hemp and cannabis producer in Colombia, today issued a shareholder update letter following the filing of its 10K Annual Report for its year ended December 31, 2022, on May 15, 2023.

The filing can be viewed here:
https://www.sec.gov/ix?doc=/Archives/edgar/data/1622244/00014931522301 ...

Dear Shareholders,

Despite the challenges we experienced with logistics and installation delays for our distillation machine, we believe 2022 was a set-up year enabling the next 12 months to be transformational as we transition into production and sales. I remain as confident as ever in One World Products, having personally invested $3 million in the Company to-date. I am pleased to provide the following detailed informational update, which outlines our achievements thus far and delineates our plans for the future.

Our first cultivation site is located in Popayan, Colombia and our extraction facility will be located in the outskirts of Bogota, Colombia, in the town of Mosquera. Our cultivation facility encompasses approximately 30 acres and includes a covered greenhouse built specifically to cultivate high-grade cannabis and hemp. In addition, we have forged agreements with local farming co-operatives that include small farmers and indigenous tribe members. Under these agreements, they will cultivate cannabis on up to approximately 140 acres of land using our seeds and propagation techniques, and sell their harvested products to us on an exclusive basis.

We employ modern propagation and cultivation techniques drawn from U.S. practices that allow us to rapidly multiply the cells of a specific plant strain to produce large numbers of genetically consistent progeny plants using our own plant tissue culture method. We believe this technique allows us to cultivate plants which are stable, robust, and able to produce genetically superior cannabis and hemp-derived products. We are committed to adhering to international quality standards. As such, we intend to certify our processes and products as compliant with Good Agricultural Practices (“GAP”), Good Manufacturing Practice (“GMP”), and the standards outlined in EU Pharmacopoeia—a publication setting forth quality standards applicable to the European pharmaceutical industry.